Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ospemifene effects on brain activation in postmenopausal women with sexual interest-arousal disorder
2020-001514-38Phase 4Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ospemifene in vaginal atrophy and female sexual arousal disorder (FSAD) (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Change in brain activation patterns after sexual stimuli. Started Jul 2020; status: completed.
02
Drugs
ospemifene
03
Conditions
vaginal atrophyfemale sexual arousal disorder (FSAD)
Beyond the preview
Go deeper on 2020-001514-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001514-38.